We’re creating powerful antibody-based biological drugs to form the basis of next-generation therapeutics.
We’re focused on treating human diseases by developing potent new biological drugs. We study how antibodies (a natural product of the immune system) switch the immune system on and off. We also study how we can use this to kill unwanted cancers and infections or prevent destructive inflammation and allergies.
Every antibody is composed of 2 functional parts that provide 2 distinct roles: the Fab and Fc. The Fab is unique in each antibody and specifically detects a target. Importantly, the Fc portion is common to all antibodies. Our focus is on activating the immune system through the antibody’s Fc portion – the part that initiates or controls the effector responses.
Our discoveries of how to transform the immune activation responses in one antibody can transform the action of all. This has broad implications for new treatments across cancer, inflammation and infectious diseases.
Stellabody® hexamer technology, a simple modification in the Fc-portion, is one of our key discoveries.
It’s a simple but revolutionary and multifaceted technology that has wide-ranging implications for the generation of new biological drugs. Using Stellabody®, we can transform the actions of antibodies to be up to 100 times more effective at cell killing.
We've discovered how to selectively engage and ‘switch off’ the cells that initiate and drive inflammation, targeting specific inflammatory cells in autoimmune and allergic diseases.
Stellabody® is up to 100 times more effective at cell killing than standard antibody therapeutics.
Burnet Institute has entered into a Research Licence and Option Agreement with biopharma company argenx for a ground-breaking technology able to transform the way we approach cancer, inflammation and infectious disease treatment.
This slide deck contains information about the Stellabody® technology and our associated patents.
Stellabody Burnet Institute [PDF 2.5 MB]